What is it about?
CYP2C19 genotype affect to efficacy of clopidogrel, one of the main treatment of cardiovascular disease. Poor metabolizer leading to more recurrent cardiovascular events, both ischemic stroke and myocardial infarction, so checking genotype before prescribing clopidogrel should be considered.
Featured Image
Photo by Keith Tanner on Unsplash
Why is it important?
Stroke is second leading cause of death and disability worldwide. Prescribing clopidogrel in poor metabolizer group will lead to treatment failure, recurrent cardiovascular event both stroke and myocardial infarction. Checking genotype before using clopidogrel will make more favorable outcome in treatment.
Perspectives
There are no recommendation about checking CYP2C19 genotype before prescribing clopidogrel but our and many studies found that treatment outcome is difference between poor and normal metabolizer. I hope that our papers will be one of many studies that help clinician aware about this facts.
Chaisak Dumrikarnlert
Bangkok International Hospital
Read the Original
This page is a summary of: CYP2C19 Genotype and Stroke Risk Score: Implications for Clopidogrel Therapy and Recurrent Events, The Open Neurology Journal, May 2025, Bentham Science Publishers,
DOI: 10.2174/011874205x374552250512160349.
You can read the full text:
Contributors
The following have contributed to this page
